Error loading player: No playable sources found
4275
Gut Microbiome — Ally or Foe for Immune Checkpoint Inhibitors
Date
May 20, 2024
SOCIETY: AGA This session will explore the complex dynamics between the gut microbiome and immune checkpoint inhibitors, addressing whether specific microbes/metabolites enhance therapeutic outcomes acting as allies or present challenges as potential foes, impacting treatment efficacy and associated side effects.
Moderators
Mayo Clinic
Stanford University
Related Products
Basic Mechanism of Tissue Repair and Injury
TFF2+ GASTRIC CORPUS PROGENITORS DIRECTLY CONTRIBUTE TO THE DEVELOPMENT OF METAPLASIA/SPEM
Epithelial Junctions and Barrier Function
MECHANOGATED ION CHANNEL PIEZO2 TETHERS TO THE ACTOMYOSIN CYTOSKELETON IN INTESTINAL EPITHELIAL MECHANORECEPTORS
Irritable Bowel Syndrome in Inflammatory Bowel Disease: Boundaries Along a Continuum
SOCIETY: AGA IBS-like symptoms in patients with IBD are common, yet presenting a diagnostic and clinical challenge for patients and their providers…
